Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Portfolio Pulse from
Actinium Pharmaceuticals published positive trial results for Actimab-A + CLAG-M in relapsed/refractory AML patients, showing promising survival rates and remission in high-risk cases. This supports their planned Phase 2/3 trial.
March 17, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharmaceuticals announced positive results from their Actimab-A + CLAG-M trial in AML patients, showing significant survival and remission rates. This supports their upcoming Phase 2/3 trial.
The publication of positive trial results in a peer-reviewed journal is a significant milestone for Actinium Pharmaceuticals. The data shows promising survival and remission rates, particularly in high-risk AML patients, which is likely to boost investor confidence and positively impact the stock price. The planned Phase 2/3 trial further supports the potential for future success.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100